[EN] N-[2-(2-AMINO-6,6-DISUBSTITUTED-4, 4A, 5, 6-TETRAHYDROPYRANO [3,4-D][1,3] THIAZIN-8A (8H)-YL) -1, 3-THIAZOL-4-YL] AMIDES<br/>[FR] N-[2-(2-AMINO-6,6-DISUBSTITUÉS-4,4A,5,6-TÉTRAHYDROPYRANO[3,4-D][1,3]THIAZIN-8A(8H)-YL)-1,3-THIAZOL-4-YL]AMIDES
申请人:PFIZER
公开号:WO2017051276A1
公开(公告)日:2017-03-30
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), and the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
本发明涉及所披露的化合物、互变异构体和该化合物的药用可接受盐,其中所述化合物具有式(I)的结构,变量R1、R2和R3如规范中所定义。还披露了相应的药用组合物、治疗方法、合成方法和中间体。
[EN] TETRAHYDROPYRANO[3,4-D][1,3]OXAZIN DERIVATIVES AND THEIR USE AS BACE INHIBITORS<br/>[FR] DÉRIVÉS DE TÉTRAHYDROPYRANO[3,4-D] [1,3]OXAZINE ET LEUR UTILISATION EN TANT QU'INHIBITEURS DE BACE
申请人:PFIZER
公开号:WO2017051303A1
公开(公告)日:2017-03-30
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula (I), wherein the variables R1, R2, R3, R4 and X are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
本发明涉及所披露的化合物、互变异构体和该化合物的药学上可接受的盐,其中该化合物具有公式(I)的结构,其中变量R1、R2、R3、R4和X如规范中定义。还披露了相应的药物组合物、治疗方法、合成方法和中间体。
[EN] N-[2-(3-AMINO-2,5-DIMETHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES USEFUL AS BACE INHIBITORS<br/>[FR] N-[2-(3-AMINO-2,5-DIMÉTHYL-1,1-DIOXIDO-5,6-DIHYDRO-2H-1,2,4-THIADIAZIN-5-YL)-1,3-THIAZOL-4-YL] AMIDES UTILES COMME INHIBITEURS DE BACE
申请人:PFIZER
公开号:WO2017051294A1
公开(公告)日:2017-03-30
The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, wherein the variables R1, R2 and R3 are as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
本发明涉及所披露的化合物、互变异构体和该化合物的药用可接受盐,其中该化合物具有如下式I的结构,其中变量R1、R2和R3如规范中所定义。同时也披露了相应的药用组合物、治疗方法、合成方法和中间体。